Paul Marr

Aug 07, 2017

MDxHealth has appointed Paul Marr to the post of executive VP of sales for North America. Marr previously served as VP of sales, North America for Beckman Coulter, and also has worked for Hologic, Gen-Probe, Leica Biosystems, Bayer Diagnostics, and Siemens Healthcare. He joins MDxHealth, which is based in Belgium, in conjunction with the firm's expansion of its US sales force to 50 representatives.

More Like This

Oct 23, 2017

Daniel Siegel

DermTech has appointed Daniel M. Siegel to its scientific advisory board. Siegel is currently a clinical professor of dermatology at SUNY Downstate. He has served as president of the American Academy of Dermatology and is a past member of both the Academy's board of directors and its coding and reimbursement task force. 

Oct 18, 2017

Olivier Elemento and Anshul Kundaje

Freenome has announced the formation of its scientific advisory board including inaugural members Olivier Elemento and Anshul Kundaje.

Elemento is director of the Englander Institute for Precision Medicine, head of the Cancer Systems Biology Laboratory, and associate professor of computational genomics in computational biomedicine at Weill Cornell Medical College. He also serves as co-assistant dean for scientific computing, associate director of the Institute for Computational Biomedicine, and co-chair of the Genetics, Epigenetics and Systems Biology Program at the Meyer Cancer Center. 

Kundaje is an assistant professor of genetics and computer science at Stanford University, focused on computational regulatory genomics. He previously led integrative analysis efforts for the ENCODE Project and the Roadmap Epigenomics Project. 

According to Freenome, the new SAB will work closely with the company's management team to advance the development of the firm's technology platform and commercial disease screening products.

Oct 17, 2017

Alexander Spyridon Baras, Anthony Magliocco, Michael Roehrl, Andries Zijlstra.

Digital pathology solutions firm Proscia has formed its board of directors. They comprise Alexander Spyridon Baras, Anthony Magliocco, Michael Roehrl, and Andries Zijlstra. Baras heads precision medicine informatics and bioinformatics at the Sidney Kimmel Comprehensive Cancer Center and the molecular diagnostics laboratory at Johns Hopkins University. He also oversees the oncology tissue services laboratory and the digital pathology slide scanning serving of the lab, along with the department of pathology.

Magliocco is the chair of anatomic pathology and excecutive director of esoteric laboratory services at the Moffitt Cancer Center. He also serves as the scientific director of the Moffitt Tissue Core. Roehrl is the founding director of the Precision Pathology Center at Memorial Sloan Kettering Cancer Center. Zijlstra is associate professor of pathology, microbiology, and immunology at Vanderbilt University.

Oct 17, 2017

Edgar Braendle

Former ARUP Laboratories President and CEO Edgar Braendle has accepted a new role as executive vice president, head of research and development, and chief medical officer of Boston Biomedical, a developer of next-generation cancer therapeutics. ARUP announced in August that Braendle, who had headed the lab company for one year, was leaving to pursue new opportunities. Prior to working at ARUP, Braendle had worked at Novartis Medicines, where he led the company's precision medicine approach, delivering complementary and companion diagnostics. At Boston Biomedical, he will report to CEO Patricia Andrews.

Oct 17, 2017

Kathryn McKenzie

Kathryn McKenzie has been appointed principal accounting officer and vice president of finance at NeoGenomics. Previously, she worked for Chico's FAS in several roles including assistant controller and director of financial reporting and treasury. She was also previously an audit manager for Ernst and Young.

Oct 13, 2017

Fred Hirsch

Biocept said that Fred Hirsch has joined its clinical advisory board. Hirsch is a professor of medicine and pathology at the University of Colorado Cancer Center.

Oct 11, 2017

Tom Civik

Tom Civik has been appointed as chief commercial officer of Foundation Medicine and will start his new position in mid November. Most recently, he was a vice president and franchise leader at Genentech, where he was responsible for several oncology products. Earlier, he held various commercial positions at Sanofi-Synthelabo. Civik holds a BA from St. Norbert College and a master's degree in business administration from the Kellogg School of Management at Northwestern University.

Oct 10, 2017

John Kenny

John Kenny has been appointed CEO of Meridian Bioscience, effective Oct. 9. He replaces John Kraeutler who is stepping down to become executive chairman. Kraeutler announced in May his plans to resign from the company as CEO. Kenny also was appointed to Meridian's board, effective Oct. 9. Kenny was most recently senior vice president, general manager, North America at Siemens Healthcare. He has also held executive level roles at Becton Dickinson, Leica Biosystems, and Quest Diagnostics.

Oct 03, 2017

Alan Copperman

Alan Copperman has joined health information firm Sema4 as its chief medical officer. Copperman is director of the division of reproductive endocrinology and infertility, and vice chairman of the department of obstetrics, gynecology, and reproductive science at the Icahn School of Medicine at Mount Sinai. He also is managing partner at Reproductive Medicine Associates of New York. 

Oct 03, 2017

Jeffrey Rona

Jeffrey Rona has resigned from his position as CFO of Great Basin Scientific, effective October 6, 2017.

Oct 03, 2017

Paul Eros

Novacyt has appointed Paul Eros as commercial director, effective Nov. 1. Eros joins Novacyt from DiaSorin, where he was VP of molecular marketing for more than five years. He has also worked for Becton Dickinson and Roche Diagnostics

Oct 03, 2017

Jeffery Luber

Atlas Genetics announced today that Jeffrey Luber has been appointed CEO and John Clarkson, current founding CEO, will become Executive Chairman. Mr. Luber joins the board with experience in the life sciences industry, including roles in both public and private companies. Most recently, he led the return to growth and sale of Good Start Genetics to Invitae. Prior to this, Luber was CEO of Exact Sciences, where he executed its turnaround and strategic transaction with Genzyme. 

Oct 02, 2017

Doug Fisher, Jeffrey Cossman

Precipio has elected Doug Fisher and Jeffrey Cossman to its board in order to fill existing vacancies. Fisher will serve on Precipio's audit committee and compensation committee. Cossman will serve on the company's compensation committee and will chair the nominating and corporate governance committee. 

Fisher is currently executive-in-resident at venture capital firm InterWest Partners, where he has worked since March 2009. He is also chief business officer at Sera Prognostics. Cossman is founder of the United States Diagnostic Standards, where he also served as CEO and chairman. Prior to that, he was CSO and a member of the board of The Critical Path Institute and as medical director of Gene Logic. 

Sep 29, 2017

Michael Epplen

Michael Epplen has been promoted to president of Sunquest Information Systems. Epplen had been serving as chief operating officer of Sunquest as well as president of Atlas Medical, which Sunquest parent company Roper Technologies acquired two years ago. He previously spent five years as CEO of Data Innovations, another company that Roper bought in 2015.

Sep 29, 2017

Timothy Ring and David Melcher

Becton Dickenson announced today that Timothy Ring and David Melcher have joined its board of directors. Ring has served as chairman and CEO of Bard since August 2003. He previously joined Bard in 1992 and has served as VP of human resources, group VP of Bard International, and in additional roles. Ring is also a director of Quest Diagnostics, a trustee for the New Jersey Health Foundation, and a board member for the Advanced Medical Technology Association. Melcher has been president and CEO of the Aerospace Industries Association since 2015. Prior to AIA, Melcher was president and CEO of Exelis, a spinoff of ITT Corporation. In addition to being a director for Bard, Melcher is also a member of the Federal Aviation Administration's NextGen Advisory Committe, providing advice on policy-level issues for US aviation modernization.